A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Dec 2015 Primary endpoint (Progression-free survival for patients 60 years of age and older) has not been met as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 03 Feb 2014 According to ClinicalTrials.gov record planned end date changed from 1 Nov 2013 to 1 Apr 2013.